Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model

Cancer Science

Volumn 103, Issue 2, 2012, Pages 325-333

  Chen, Jianxiang ^a   Yang, Bingya ^a   Cheng, Xiawei ^a   Qiao, Yiting ^a   Tang, Bo ^a   Chen, Guo ^a   Wei, Jing ^a   Liu, Xiufeng ^a   Cheng, Wei ^a   Du, Pan ^a   Huang, Xiaofeng ^a   Jiang, Wenhui ^a   Hu, Qingang ^a   Hu, Yiqiao ^a   Li, Jiahuang ^a   Hua, Zi Chun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VNP 20009;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; GENE THERAPY; HYPOXIA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BACTERIAL PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; SALMONELLA TYPHIMURIUM; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84856455259     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02147.x     Document Type: Article

References (48)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
2. Dachs GU, Patterson AV, Firth JD et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-20.
3. Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998; 79: 365-9.
4. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-43.
5. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 2005; 117: 701-8.
6. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999; 80: 617-23.
7. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
8. Leschner S, Weiss S. Salmonella-allies in the fight against cancer. J Mol Med 2010; 88: 763-73.
9. Li YH, Guo KY, Chen H et al. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer 2001; 94: 438-43.
10. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Inhibition of tumor growth using Salmonella expressing Fas ligand. J Natl Cancer Inst 2008; 100: 1113-6.
11. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 2007; 104: 12879-83.
12. Chen JX, Wei DP, Zhuang HQ et al. Proteomic screening of anaerobically regulated promoters from Salmonella and its antitumor applications. Mol Cell Proteomics 2011; 10(6): M111.009399.
13. Bereta M, Hayhurst A, Gajda M et al. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine 2007; 25: 4183-92.
14. Luo X, Li ZJ, Lin S et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res 2001; 12: 501-8.
15. Clairmont C, Bermudes D, Low KB et al. VNP20009, a genetically modified Salmonella typhimurium: anti-tumor efficacy, toxicology, and biodistribution in preclinical models. Clin Cancer Res 1999; 5: 3830S.
16. King I, Lin S, Le T et al. Tumor-selective colonization of VNP20009 in mice, rats, and dogs. Cancer Gene Ther 2001; 8: 690.
17. Jia LJ, Wei DP, Sun QM et al. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 2007; 121: 666-74.
18. Loessner H, Endmann A, Leschner S et al. Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol 2007; 9: 1529-37.
19. Nishikawa H, Sato E, Briones G et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006; 116: 1946-54.
20. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57: 4537-44.
21. King I, Bermudes D, Lin S et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther 2002; 13: 1225-33.
22. Fecker LF, Ruckert S, Kurbanov B et al. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenoviral armed with TNF-related apoptosis inducing ligand. Hum Gene Ther 2010; 4: 405-17.
23. Li X, Fu GF, Fan YR et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-11.
24. Patyar S, Joshi R, Byrav DSP, Prakash A, Medhi B, Das BK. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010; 17: 21.
25. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004; 113: 58-64.
26. Chatfield SN, Charles IG, Makoff AJ et al. Use of the Nirb promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains - development of a single-dose oral tetanus vaccine. Biotechnology 1992; 10: 888-92.
27. Foynes S, Holley JL, Garmory HS, Titball RW, Fairweather NF. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F HC fragment. Vaccine 2003; 21: 1052-9.
28. Ruiz-Perez F, Leon-Kempis R, Santiago-Machuca A et al. Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect Immun 2002; 70: 3611-20.
29. Xu DM, McSorley SJ, Tetley L et al. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium. J Immunol 1998; 160: 1285-9.
30. Al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H et al. Attenuated bacteria as effectors in cancer immunotherapy. Recent Adv Clin Oncol 2008; 1138: 351-7.
31. Salam MA, Katz J, Zhang P, Hajishengallis G, Michalek SM. Immunogenicity of Salmonella vector vaccines expressing SBR of Streptococcus mutans under the control of a T7-nirB (dual) promoter system. Vaccine 2006; 24: 5003-15.
32. Salam MA, Katz J, Michalek SM. Role of Toll-like receptors in host responses to a virulence antigen of Streptococcus mutans expressed by a recombinant, attenuated Salmonella vector vaccine. Vaccine 2010; 28: 4928-36.
33. Santiago-Machuca AE, Ruiz-Perez F, Delgado-Dominguez JS, Becker I, Isibasi A, Gonzalez-Bonilla CR. Attenuated Salmonella enterica serovar typhi live vector with inducible chromosomal expression of the T7 RNA polymerase and its evaluation with reporter genes. Plasmid 2002; 47: 108-19.
34. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 2008; 7: 851-61.
35. Gahan ME, Webster DE, Wesselingh SL, Strugnell RA. Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium. Vaccine 2007; 25: 1476-83.
36. Tomilov AA, Bicocca V, Schoenfeld RA et al. Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice. J Biol Chem 2010; 285: 1153-65.
37. Doekhie FS, Mesker WE, Kuppen PJ et al. Detailed examination of lymph nodes improves prognostication in colorectal cancer. Int J Cancer 2010; 126: 2644-52.
38. Hautefort I, Proenca MJ, Hinton JCD. Single-copy green fluorescent protein gene fusions allow accurate measurement of Salmonella gene expression in vitro and during infection of mammalian cells. Appl Environ Microbiol 2003; 69: 7480-91.
39. Smyth MJ, Crowe NY, Pellicci DG et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002; 99: 1259-66.
40. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006; 28: 84-94.
41. Taniguchi S, Fujimori M, Sasaki T et al. Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci 2010; 101: 1925-32.
42. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-25.
43. Newton SMC, Klebba PE, Hofnung M, Charbit A. Studies of the anaerobically induced promoter pnirB and the improved expression of bacterial-antigens. Res Microbiol 1995; 146: 193-202.
44. Everest P, Frankel G, Li JL, Lund P, Chatfield S, Dougan G. Expression of LacZ from the htrA, nirB and groE promoters in a Salmonella vaccine strain - influence of growth in mammalian-cells. FEMS Microbiol Lett 1995; 126: 97-101.
45. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007; 85: 1301-7.
46. Harris AL. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
47. Moulder JE, Rockwell S. Tumor hypoxia - its impact on cancer-therapy. Cancer Metastasis Rev 1987; 5: 313-41.
48. Wang SL, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-33.